Increased interleukin-32 expression in chronic hepatitis B virus-infected liver
β Scribed by Xu, Qihuan; Pan, Xingfei; Shu, Xin; Cao, Hong; Li, Xuejun; Zhang, Ka; Lu, Jianxi; Zou, Yong; Li, Xueling; Liu, Hongcan; Zhang, Yeqiong; Yang, Daofeng; Ning, Qin; Shen, Guanxin; Li, Gang
- Book ID
- 119298805
- Publisher
- Elsevier Science
- Year
- 2012
- Tongue
- English
- Weight
- 738 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0163-4453
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
An analysis of the expression of the histocompatibility antigens in the livers of patients with chronic hepatitis B virus infection and normal subjects has demonstrated an increased expression of HLA-A,B,C antigens on the hepatocytes of patients with a low level of viral replication (HBe antibody po
Human hepatitis B virus (HBV) and hepatitis C virus (HCV) are two major etiologic agents of chronic hepatitis, which is closely related to the development of hepatocellular carcinoma (HCC). A possible involvement of HBV co-infection was investigated in ongoing HCV-related liver diseases in HCV-infec
In a previous study a partial inhibition of viral replication was observed in HBeAg-positive patients after acyclovir (ACV) treatment. To assess those results and to evaluate different treatment regimens, a randomized controlled trial with ACV given at 45 mg/kg/day by continuous infusion (in 5 pati
to be controlled for in comparing immunoprophylactic approaches. At present, DNA polymerase activity or HBV DNA is useful for estimating the level of exposure. In an editorial in this issue, Dr. Dienstag pointed out difficulties in comparing the results of two immunoprophylactic regimens conducted a